Antibe Therapeutics Inc(Pre-Merger) ATBPF

RE:RE:RE:RE:RE:RE:RE:RE:RE:Upcoming ...

[Benedictus]

MrMugsy wrote:

Benedictus wrote:

MrMugsy wrote:

woundedknee wrote: About time for Dan to sell some more of his shares. Christmas bills coming up. lol

Hahaha - I don't think it works that way but I could be wrong.

I think he covered some future capital gains on the sale of Antibe Holdings - but - maybe I'm wrong.  I would have done that myself.

Also - I'd be more concerned about unexpected sales like the one by Wallace out of nowhere.  The unknown and unexpected is a little harder to swallow.  Then again, to sell at lows is more preferred than selling at highs - I respect that part of Wallace's sale.

Going forward - don't think we'll see any selling from Dan/John as we head into P2 excitement.  Just my opinion.

Personally - I would have taken some of our cash and used it to buyback shares at this level - or at least threaten to do so.  It would have been the absolute wrong approach with our cash ... but I would have threatened it none-the-less.         : )

 

Mugs, I always appreciate your insights and optimism but a share buyback threat would have been an awful bluff and a tell of inept management.  They need every damn penny on hand and then some...and the market knows it.  I'm pleased they're just sticking to their knitting, don't need to dilute near term and moving everything forward. 2023 should be a better year for the longs and within 12 months, give or take, we will have successful acute p2 results. 

I agree Benedictus ... I'm just kidding.

By the end of 2022, we'll have $42.5 MM in the bank and we need a minimum of 2 years runway.
We also need cash on hand to pay for specialists as situations call for it.

I think we spent $2 MM on Liver Specialists.
We probably spent some money figuring out the amorphous solution.
I wouldn't doubt we spent money developing a superoxide scavenger already (Antiviral ?)
We're looking at an IV form of OTENA.
Figuring out if we need 352 in a head-to-head study now.
And ... who knows what wacky and wonderful things are coming in our IBD drug.

The cash is key for development work and it keeps us in the driver seat during OTENA negotiations.

 

Yes and hopefully the quarterly burn rate is a little lower with acute than chronic. I appreciated Dan stressing their intention toward financial prudence. Capital is obviously extremely hard to come by nowadays. A 352 head to head comparison would be very interesting.